Research in the HIV field aims at reacting to new developments. We conduct studies regarding clinical-epidemiological questions such as immune recovery under therapy as well as prospective therapeutic trials. In addition, we aim at improving the safety and use of the antiretroviral therapy by studying drug-related toxicity and drug-interactions issues, and by defining the optimal time to start therapy. The HIV clinic of Basel is one of the Centers of the Swiss HIV Cohort Study and many studies are conducted within the frame of this observational, prospective, multi-center study.

Specific research topics

  • Description of clinical course with and without therapy (CD4-T cell course, projects regarding best choice of therapy for specific patient groups).
  • Prospective phase II and III studies.
  • Studies in the medico-social and economic field.
  • Pathophysiological studies in collaboration with the Institute of Medical Microbiology Basel and other Swiss groups within the frame of the Swiss HIV Cohort Study.

Patient's readiness to start ART (READY Projekt)

  • We study patient readiness to HIV treatment and aim at developing teaching tools to increase communication quality of health care providers.

Drug-drug interactions

  • Potentially clinically relevant drug interactions have become a major issue in HIV therapy due to the ageing of the HIV-infected patients and increasing prevalence of co-medications. We aim at studying drug interactions that are challenging for HIV therapy.


  • Adverse events to combination antiretroviral therapy are common reasons for treatment modification and poor adherence. We investigated predictors of treatment modification within the Swiss HIV Cohort Study. Although toxicity remains a frequent reason of treatment change, possibly due to the broad availability of alternative antiretroviral drugs, it does not alter treatment success. Close monitoring and management of side effects and drug-drug interactions are crucial for durability of cART.